About ethris
ethris develops innovative therapeutics based on proprietary platform technologies with high potential for diversification, enabling new therapies for previously untreatable diseases. Magnetovax®is a platform for personalized tumor vaccination that is locally and tumor-specifically activated by magnetic fields. SNIM®RNA is a first-in-class biopharmaceutical platform for new therapies of rare diseases, the replacement of recombinant proteins and as "transcript therapy" in regenerative medicine. ethris "enabling therapies" provide access to highly profitable markets. ethris was founded at the end of 2009 by PD Dr. Carsten Rudolph and Prof. Dr. Christian Plank, who are also the company's managing directors. In the same year, the two scientists from Ludwig-Maximilians-Universität and Technische Universität München were able to win Dr. Walter Schmidt (CEO, Affiris AG, Vienna) as a business angel. Since the end of 2011, the HS Lifesciences GmbH has held a stake in ethris GmbH. ethris has set itself the goal of bringing new therapies into clinical trials in rapid succession on the basis of its globally unique expertise.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Founding: 2009
- Focus : Manufacturer
- Industry : Pharma
